AAV & lentiviral vector titer determination: past, present, & future

Cell & Gene Therapy Insights 2023; 9(9), 1161–1174

DOI: 10.18609/cgti.2023.154

Published: 1 November
Innovator Insight
Mark White, John Bechill, Peng Wang

Viral titer determination is essential to the safe and effective dosing of gene therapy products, but methods used to measure viral titer are still improving and evolving. In this article, Mark White (Associate Director, Biopharma and Translational Product Marketing, Digital Biology Group, Bio-Rad), John Bechill (Principal Scientist, BioProcess Group, Modalis Therapeutics), and Peng Wang (Senior Scientist, Viral Vector Analytical Team Lead, Lonza) discuss the need for accurate viral titer determination, traditional approaches to measuring viral titer, and the field’s trajectory into the future.